Baer Jefferson T, Sauer William H, Berlin Jesse A, Kimmel Stephen E
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Am J Cardiol. 2004 Aug 15;94(4):479-81. doi: 10.1016/j.amjcard.2004.04.063.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have slightly different mechanisms of action. As such, it has been hypothesized that these 2 classes of medications differ in their ability to prevent myocardial infarction. In the present case-control study, we found no difference between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of nonfatal myocardial infarction among patients with hypertension.
血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的作用机制略有不同。因此，有人推测这两类药物在预防心肌梗死的能力上存在差异。在本病例对照研究中，我们发现血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在高血压患者非致命性心肌梗死的一级预防中没有差异。
